한미약품

128940KOSPI의약품 제조업

53.5 / 100

Reference Date: 2026-07-24

Financial Score17.5 / 40

News Sentiment19.1 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Slightly down 3.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanmi Pharmaceuticals operates in three segments: pharmaceuticals, APIs, and overseas pharmaceuticals. It produces and sells key drugs such as the hypertension treatment 'Amozaltan' and has a global presence through its API division, Hanmi Precision Chemicals, which holds international certifications like FDA. Its overseas subsidiary, Beijing Hanmi, focuses on pediatric medications and hypertension treatments in the Chinese market.

Number of Employees

2,382people

Average Salary

86.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

29.09Industry Average 11.230.0Point

2.6x industry avg (risky)

PBR

3.50Industry Average 0.810.0Point

4.3x industry avg (risky)

ROE

14.05Industry Average 4.017.0Point

3.5x industry avg (excellent)

Debt Ratio

7.70Industry Average 12.435.0Point

Lower than industry avg (good)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 13.9% (declining, 3yr)

Detailed News Sentiment

33 totalPositive 26Neutral 5Negative 2Average Sentiment Score 76.2

Neutral
SK네트웍스가 육성한 피닉스랩, '800만 달러' 투자 라운드 진행
SK네트웍스의 AI 스타트업 피닉스랩이 케이론을 통해 바이오파마 시장 진출을 모색하고 있으나, 한미약품과 직접적인 연관성이 없어 중립적 평가.
Positive
HLB, 간암 신약 허가 불발 전부터 美 상업화 채비…보험 적용 인력 ...
한미약품의 간암 신약 관련 미국 상업화 준비가 진행 중이며, 보험 적용 인력 채용 공고로 인해 긍정적인 시장 반응이 예상됩니다.
Positive
영업 인력만 600명…한미 뛰어든 韓 비만약 ‘춘추전국시대’ 열린다
한미약품의 신규 비만약 출시로 경쟁 구도가 복잡해져 시장 점유율 경쟁이 치열해질 것으로 예상되며, 이는 기업의 성장 기회를 확대시킬 것입니다.

Detailed Momentum

52-week position3.0Point

52w lower range (33%)

Current 389,000Won52-week high 626,00052-week low 270,000

1-month return2.0Point

1m -3.47% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral기업설명회(IR)개최(안내공시)2026-07-14
Neutral결산실적공시예고(안내공시)2026-07-14
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-07-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-02